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oropharyngeal cancer patients for proton therapy
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Patrick V. Grantona , Steven F. Petita and Mischa S. Hoogemana
aDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; bDepartment of Radiation Oncology, LUMC,
Leiden, The Netherlands
ABSTRACT
Background: Proton therapy is becoming increasingly available, so it is important to apply objective
and individualized patient selection to identify those who are expected to benefit most from proton
therapy compared to conventional intensity modulated radiation therapy (IMRT). Comparative treat-
ment planning using normal tissue complication probability (NTCP) evaluation has recently been pro-
posed. This work investigates the impact of NTCP model and dose uncertainties on model-based
patient selection.
Material and Methods: We used IMRT and intensity modulated proton therapy (IMPT) treatment plans
of 78 oropharyngeal cancer patients, which were generated based on automated treatment planning
and evaluated based on three published NTCP models. A reduction in NTCP of more than a certain
threshold (e.g. 10% lower NTCP) leads to patient selection for IMPT, referred to as ‘nominal’ selection.
To simulate the effect of uncertainties in NTCP-model coefficients (based on reported confidence inter-
vals) and planned doses on the accuracy of model-based patient selection, the Monte Carlo method
was used to sample NTCP-model coefficients and doses from a probability distribution centered at
their nominal values. Patient selection accuracy within a certain sample was defined as the fraction of
patients which had similar selection in both the ‘nominal’ and ‘sampled’ scenario.
Results: For all three NTCP models, the median patient selection accuracy was found to be above 70%
when only NTCP-model uncertainty was considered. Selection accuracy decreased with increasing
uncertainty resulting from differences between planned and delivered dose. In case of excessive dose
uncertainty, selection accuracy decreased to 60%.
Conclusion: Model and dose uncertainty highly influence the accuracy of model-based patient selec-
tion for proton therapy. A reduction of NTCP-model uncertainty is necessary to reach more accurate
model-based patient selection.
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Introduction
Normal tissue complication probability (NTCP) models have
been proposed by Langendijk et al. as a patient-selection
tool for new treatment techniques. Their model-based
approach uses NTCP-based treatment plan evaluation to ana-
lyze NTCP reduction (DNTCP) between two alternative techni-
ques. Patients for which DNTCP exceeds a certain threshold
will be selected for the new treatment technique [1].
Model-based patient selection is particularly useful when
outcome of clinical trials is lacking and treatment availability
is limited. Intensity modulated proton therapy (IMPT) in
head-and-neck cancer is an example of a promising, compli-
cation reducing, technique that is more costly and limited in
capacity compared to intensity modulated radiation therapy
(IMRT) [2–5]. Langendijk et al. and Hoogeman et al. investi-
gated the use of a model-based approach for selection of
only those patients that benefit most from IMPT compared
to IMRT [1,6].
This paper investigates the currently unknown impact of
uncertainty in the used NTCP models and planned dose on
selection accuracy of oropharyngeal cancer patients and
thereby the clinical usefulness of the model-based approach.
NTCP-model uncertainties, represented by confidence inter-
vals (CIs), are included in the publication of the models. Dose
uncertainties are generally originating from the differences
between planned and delivered dose e.g. induced by anat-
omy changes during the treatment course [7]. Although
these differences are included in the model building, system-
atic differences between photon and proton treatments may
impact the accuracy of patient selection. A Monte Carlo
based approach is used to consider the impact of both sour-
ces of uncertainty on the accuracy of patient selection.
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Material and methods
Patients and treatment planning
The anonymized CT-scans of 78 oropharyngeal patients
treated with IMRT at the Leiden University Medical Center
(24 patients) and the Erasmus MC Cancer Institute (54
patients) were used in this study, see Table 1 for the baseline
characteristics. Automated treatment planning was used to
generate comparable IMRT and IMPT plans to avoid user-
dependence on treatment plan quality and enable objective
and efficient patient selection [8,9]. The clinical target vol-
umes (CTV) were taken as used clinically. The delineations of
the organs at risk were adapted if necessary to comply to
the NTCP models used in this study. Dose was prescribed
according to a 35 fraction simultaneously integrated boost
(SIB) scheme, with a prescription of 70GyRBE to the primary
tumor and pathological lymph nodes (LUMC) or levels with
pathological lymph nodes (Erasmus MC) and 54.25GyRBE to
the elective nodal areas. For IMPT, minimax robust optimiza-
tion was used to compensate for rigid and non-rigid patient
setup errors, consisting of setup robustness (SR) and range
robustness (RR) [10]. Nine error scenarios were considered:
six scenarios in the positive and negative direction along
three axes, two scenarios simulating a positive and negative
range error and one nominal scenario (no errors). Setup error
scenarios were simulated by laterally shifting the pencil
beams, while range error scenarios were generated by alter-
ing the proton energy. For IMRT, margins were added to
expand the clinical target volume (CTV) to the planning tar-
get volume (PTV). IMRT was planned using 23 equi-angular
beams of 6MV and a dynamic multi-leaf collimator, mimick-
ing a volumetric arc therapy (VMAT) capable dose distribu-
tion. For IMPT, a three beams setup (60, 180 and 300),
with energies ranging from 70 to 250MeV, was used as sug-
gested by Van de Water et al. [11]. A 57mm water-equivalent
range shifter was used in IMPT to reach target volumes
located close to the skin. Constant radiobiological effective-
ness (RBE) of 1.0 and 1.1 were assumed for IMRT and IMPT,
respectively [12].
Plan generation for IMRT and IMPT was performed fully
automatically using our in house developed optimizer,
Erasmus-iCycle [8,9]. This optimizer uses the CT scans and
corresponding delineations together with a user defined
wish-list to automatically generate the treatment plan. The
wish-list consists of constraints and prioritized objectives.
Constraints should always be met, while objectives are opti-
mized sequentially according to their priorities [13,14].
Comparable wish-lists for IMRT and IMPT plans were
designed in close collaboration with radiation oncologists.
The main planning goal was that 98% of the PTV (IMRT)
did receive 95% of the prescribed dose (V95%  98%) in
both the primary tumor and nodal regions. Furthermore,
V107%  2% and V110%  0% should be met for the primary
tumor. Also a visual check for hotspots and inconsistencies
was performed. For IMPT, the same goals should be met for
the CTV of the worst case robustness scenario. Minor viola-
tions in target coverage can be corrected for using a rescal-
ing of the dose distribution.
Plan comparison
Plan comparison between 3-mm-margin IMRT plans and
3-mm-SR/3%-RR robustness settings for IMPT plans was per-
formed. This choice for high precision IMRT and IMPT is
based on a robustness recipes study by Van der Voort et al.
[15] and the expectation that IMPT with 3-mm-SR/3%-RR
robustness settings will become available with technical
improvements and image-guidance [16]. As a comparison we
analyzed other combinations of margins (0, 3 and 5mm) and
SR (0, 3 and 5mm) and RR (0, 3 and 5%) robustness settings.
Note that the margin and robustness settings of choice
depend on the desirable and available treatment accuracy.
NTCP model-based patient selection
We used published NTCP models, recently proposed for
model-based patient selection in the Netherlands, as a plan
comparison and selection tool for IMRT and IMPT treatment
as proposed by Langendijk et al. and used by Hoogeman
et al. [1,6]. The left part of the flow chart in Figure 1 illus-
trates the model-based patient selection approach extended
with a Monte Carlo method to check for patient selection
accuracy. The selection referred to as ‘nominal selection’ is
retrieved according to Langendijk et al. [1], where NTCPs
based on IMPT plans are subtracted from those of the IMRT
plans, resulting in DNTCPs. If the DNTCP exceeds a pre-
defined DNTCP threshold (e.g. 10 and 5% for grade II and
grade III complications, respectively are currently prescribed
by the Dutch Society of Radiation Oncology), the patient
would be selected for IMPT instead of IMRT. We considered
three different NTCP models i.e. for grade II problems swal-
lowing solid food, decreased parotid flow and grade III tube
feeding dependence [17–19]. Details regarding the three
Table 1. Baseline patient characteristics.
Characteristics Number %
Sex
Male 58 74
Female 20 26
Age
<65 47 60
>65 31 40
T-classification
T1 4 5
T2 42 54
T3 12 15
T4 20 26
Bilateral neck irradiation
Yes 71 91
No 7 9
Weight loss (before treatment)
None 59 75
Moderate 17 22
Severe 2 3
Accelerated radiotherapy
Yes 38 49
No 40 51
Radiotherapy plus Cetuximab
Yes 14 18
No 64 82
Chemoradiation
Yes 22 28
No 56 72
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different NTCP models are provided in Table 2. Patient selec-
tions and accuracies were considered for each NTCP model
separately.
Patient selection accuracy
To investigate the impact on patient selection subjected to
two types of uncertainty, further described below (i.e. NTCP-
model uncertainty and dose uncertainty), we drew ten thou-
sand samples from a Gaussian distribution centered at the
model coefficient or planned dose values used for the nom-
inal selection. Every sampled DNTCP can be seen as an
uncertainty-based deviation from the nominal DNTCP.
Patient selection based on DNTCP was done for all samples,
after which all sample-based selections were compared to
the nominal selection. If a patient is selected for the same
modality in the sampled scenario as in the nominal scenario,
the selection is considered ’Correct’. For each sampled scen-
ario, the accuracy is the ratio between correctly selected
patients and the total number of patients (Np ¼ 78) [20]:
Accuracym ¼
P
i Correctm;i
Np
We used the median of all sample accuracies as indicator
for the overall accuracy for a specific DNTCP threshold and
NTCP model. A semi-analytical method, as a statistical more
Figure 1. Left: Flow chart of the method used. The nominal selection is based on Langendijk et al. [1]. The sampled selection takes into account uncertainty in the
NTCP models and the dose. (index i and j represent patients Correct or Failed selected, respectively, while m is sample number ranging from 1 to M). Np, refers to
the total number of patients. Right: Further elaboration of model and dose uncertainties. Hence, lan and lxn are the estimates of the nth model coefficients and
dose variables respectively, while the uncertainties are introduced via the corresponding standard deviations (SD).
Table 2. Details of NTCP models used. The mean values and the confidence intervals of the model coefficients are given.
Endpoint Grade Model type Model coefficients Mean CI
Problems swallowing food [17] II Logistic regression model Constant 1.443 [NA]
Dsuperior PCM 0.049 [0.0296–0.0677]
Dsupraglotic larynx 0.048 [0.0100–0.0862]
Age 0.795 [0.0198–1.5665]
< 25% Parotid flow for individual
parotid gland after one year [18]
II Lyman Kutcher Burman (LKB) model TD50 39.9 [37.3–42.8]
m 0.40 [0.34–0.51]
n 1 –
Tube feeding dependence after six
months [19]
III Logistic regression model Constant 11.70 [-13.47– -8.47]
Advanced T-stage 0.43 [-0.16–0.73]
Weight lossmoderate 0.95 [0.70–1.16]
Weight losssevere 1.63 [1.20–1.99]
Accelerated RT 1.20 [0.87–1.51]
Chemoradiation 1.91 [1.39–2.40]
RTþ Cetuximab 0.56 [0.40–0.70]
Dsuperior PCM 0.071 [0.044–0.082]
Dinferior PCM 0.034 [0.006–0.057]
Dcontralateral parotid 0.006 [0–0.0019]
Dcrispharyngeal muscle 0.023 [0.006–0.034]
Dx: mean dose to organ x; RT: radiotherapy; PCM: pharyngeal constrictor muscle; NA: not available.
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in-to-depth validation of this Monte Carlo method, is elabo-
rated in supplementary material 1.
NTCP-model uncertainty
Uncertainty in the NTCP models is represented by a probabil-
ity distribution of the model coefficients (an) represented by
the mean value (lan ) and corresponding confidence interval
(CIan ). Since our selection accuracy method uses the standard
deviation (SD) as a measure of uncertainty, we need to trans-
form the CIan into SDan . According to the central limit the-
orem, we know that the NTCP-model coefficients originate
from a normal probability distribution [21]. This supports the
use of the formula for normal distributions to retrieve the
standard error (SE) from the CI; CI ¼ l61:96  SE. In case of
model coefficient sampling estimates SE is known as SD [21].
Dose uncertainty
Another source of uncertainty is the difference between
planned and actually delivered doses [7]. Those differences
are not exactly known but are estimated to be in the order
of a few Gy, however, there is evidence for larger differences
as well [16,22]. Part of the dose uncertainties are already
included in the models’ uncertainty as the models have been
built from real clinical data. Additionally, systematic dose
uncertainties can be of influence on patient selection accur-
acy. Dose differences due to assumptions of constant RBE,
which might be dependent on linear energy transfer (LET)
[23] or differences in the impact of anatomy changes
between photon and proton treatments are examples of sys-
tematic dose uncertainties [7].
We analyzed the effect of increasing systematic dose
uncertainty on selection accuracy using dose volume histo-
gram (DVH) samples from a normal distribution centered at
the optimized doses (lxn ) with SDs ranging from no (0Gy) to
excessive (5 Gy) uncertainty in the doses (SDxn ) [24].
In the results section we will make a distinction between
the impact of uncertainty in the NTCP models and the add-
itional impact of systematic dose uncertainty. This is shown
because model uncertainty is a known and published source
of uncertainty, while the actual uncertainty in the dose is not.
Influence of DNTCP threshold, model improvement and
dose correlation
As a further consideration we investigated the sensitivity of
selection accuracy with respect to different DNTCP thresholds.
We also analyzed by how much selection accuracy could be
increased when uncertainty in the NTCP models is reduced.
This was done by means of a hypothetical reduction of the
model coefficient CIs by factor 2. Furthermore, the influence
of correlation between doses in different organs at risk on
selection accuracy was taken into consideration. Correlation
between dose uncertainties was introduced by changing the
dose sampling strategy from independent to dependent.
Results
Figure 2 shows that in all three models the median accuracy
level (solid black line) was above 70% based on model
Figure 2. Selection accuracy due to combined model and dose delivery uncertainty. The first box, per model, (SDdose¼ 0 Gy) represents the model uncertainty. The
subsequent grayscale boxes (SDdose>0 Gy) show the influence of increasing dose delivery uncertainty on the selection accuracy. The median of all samples (2nd
quartile) is given by the black solid line, the box around the median defines the 1st and 3rd quartile. The dashed ‘whiskers’ depict sample accuracies that are not
outliers. Outliers (þ) are defined as accuracies more than 1.5 times the interquartile distance (size of the box) away from the boxes.
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uncertainty alone. Increasing dose uncertainty resulted in the
largest accuracy drop for the decreased parotid flow model.
The median accuracy level, however, never decreased below
60% even for excessive dose uncertainties. Compared to
dose uncertainty, model uncertainty was most important in
the models for problems swallowing solid food and tube
feeding dependence. The accuracy spread was stable for the
swallowing problems and tube feeding models, while the
spread increased with dose uncertainty for the model of
decreased parotid flow.
Figure 3 shows that median accuracy levels at the cur-
rently prescribed DNTCP thresholds for grade II (III) of 10%
(5%) were near the lowest point on the curves and additional
reduction of selection accuracy with increasing dose uncer-
tainty was most severe.
Accuracy of patient selection based on plan comparison
of 3-mm-margin against 3-mm-SR/3%-RR had been consid-
ered so far. Hence, Table 3 shows that there was no general
trend for accuracy level as function of margin or robustness
setting. However, the highest accuracy levels seemed to
occur when the differences between robustness and margin
increased. The same trend was found at different levels of
dose uncertainties.
A hypothetical model improvement regarding uncertainty
in NTCP models resulted in a model accuracy increase of up
to more than 10%. The accuracy levels due to model uncer-
tainty only increased to more than 80% for all three models.
The same increase was found for the combined accuracy at a
moderate dose uncertainty level (SDdose ¼ 3Gy). The largest
gain in selection accuracy could be achieved for the models
of swallowing problems and tube feeding.
Discussion
In this study we investigated the impact of model and
dose variable uncertainties on the accuracy of patient
selection for IMPT. Patient selection based on sampled
DNTCPs, representing uncertainties in model coefficients
and doses, were compared to nominal selections. We
found median selection accuracies to range from 63% to
96%. For swallowing problems and tube feeding depend-
ence the selection accuracy was most affected by the
uncertainty in the model coefficients. Contrary for the
model of decreased parotid flow, which was most effected
by uncertainty in dose.
The relatively low impact of model uncertainties on the
selection accuracy for the decreased parotid flow model
could be explained by the fact that only two coefficients
were included in the model. Moreover, the two coefficients
were fitted to data of 222 patients and in total 384 parotid
glands from two independent cohorts [18]. The models for
swallowing problems and tube feeding contained 4 and 11
coefficients respectively, which were fitted using data of 354
Figure 3. Selection accuracy due to model coefficient (SD¼ 0 Gy)and dose (SDdose> 0 Gy) uncertainty (solid) as a function of DNTCP threshold. Patient selection
rate (dashed) shows impact of DNTCP threshold increase on patient selection. The numbers represent the values at the prescribed DNTCP.
Table 3: Accuracy as function of margin (IMRT, columns) and robustness set-
tings (IMPT, rows) at prescribed DNTCP threshold and SDdose ¼ 3 Gy.
Swallowing
problems
Decreased
flow
Tube
feeding
0mm 3mm 5mm 0mm 3mm 5mm 0mm 3mm 5mm
0 mm–0% 68 78 87 81 81 87 74 67 68
3 mm–3% 77 68 81 97 74 80 86 65 64
3 mm–5% 76 67 80 99 77 76 90 65 64
5 mm–3% 86 68 72 100 91 73 95 68 62
5 mm–5% 85 69 69 100 94 74 95 68 63
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and 355 patients [17,19] . Generally speaking, if more varia-
bles are included in multi-variable modeling, more patients
(with events) need to be included for an accurate estimate of
the model coefficients.
As a proof of concept we analyzed what impact a reduc-
tion in the uncertainty of the model coefficients could have.
The results showed that for swallowing problems and tube
feeding the selection accuracy could be improved to above
80%. Based on these findings, we recommend the inclusion
of more patients in multi-variable NTCP modeling in order to
lower the CIs.
The model for decreased parotid flow showed a large
dependence on additional uncertainties in dose. This could
be explained by the fact that NTCP values were on aver-
age located in a steeper part of the NTCP curve. This
makes the selection according to this model inherently
more sensitive to uncertainties in dose. A second reason
for the lower impact of dose uncertainty on patient selec-
tion in the models for swallowing problems and tube feed-
ing could be that complication is predicted by multiple
dose variables. In this study, dose samples were drawn
independently, while they may be correlated. Therefore, we
also investigated possible correlation between different
dose uncertainties, but this did not lead to large differen-
ces in accuracy. Selection accuracy also depends on the
DNTCP threshold. The minimum thresholds as prescribed
by the Dutch Society of Radiation Oncology resulted in
suboptimal accuracy levels (see figure 3). For the tube
feeding model the accuracy can be increased to above
80% by increasing the DNTCP threshold from 5% to 10%,
however this will also lead to less patients being selected
for proton therapy. Reduction of selection accuracy with
increasing dose uncertainty appeared to be most severe in
the region of the currently proposed DNTCP thresholds,
which underpins the importance of keeping the difference
between planned and delivered dose as low as possible.
In this study we compared 3-mm margin IMRT with
3-mm-SR/3%-RR robust IMPT. We would like to stress that
the IMRT margins and IMPT robustness settings that would
result in adequate target coverage depend on the level of
dose delivery accuracy that can be achieved with each of
the modalities. Therefore, we also determined the selection
accuracy for other combinations of margins and robustness
settings at different dose uncertainty levels. We found the
lowest accuracy for combinations of comparable margins
and robustness settings. Larger margins lead to increasing
mean doses and thus higher NTCPs for the IMRT plan. As
long as the inflection point of the NTCP-curve is not
reached, this will lead to larger DNTCPs that are further
away from the threshold. This increases the correct selec-
tion rate and thereby the selection accuracy. Accuracy
increase due to larger robustness settings can be explained
using a similar reasoning.
The main focus of this study was to investigate the influ-
ence of uncertainties on patient selection accuracy. Note that
the model-based approach will not select patients for whom
a complication will be avoided if they are treated with pro-
ton therapy. In this regard, it might be interesting to calcu-
late other metrics, which focus on the impact of
uncertainties on the expected DNTCP for patients selected
for a photon or proton treatment. For example, the ratio of
sampled DNTCP and nominal DNTCP values can be calcu-
lated for this purpose.
The dose uncertainty analysis focused on the impact of
systematic dose uncertainties (e.g. LET depended RBE)
assuming that the random dose uncertainties are already
incorporated in the model uncertainty. However, one could
think of random dose uncertainties that were not present
in the NTCP model building cohort. An example is the dif-
ference between the dose distribution used for patient
selection and that in the final deliverable treatment plan.
These differences can occur if predicted organ-at-risk DVHs,
are used for patient selection, which was proposed by
Delaney et al. [22]. In our study, we used fully generated
treatment plans for patient selection to minimize the dose
uncertainty.
A limitation of this study is that we assumed that NTCP
models derived from photon treatments are also valid for
IMPT. Recently, Blanchard et al. were the first that validated
photon derived NTCP models for patients treated with pro-
ton therapy [25]. They found that the models remained valid
suggesting that this source of uncertainty can be ignored
compared to uncertainties in model coefficients and dose.
Nevertheless, as soon as model-based patient selection is
used in clinical practice, treatment-related toxicities should
be captured prospectively in order to validate the NTCP
models for proton therapy. Another remark is the fact that
information about confidence intervals was missing for the
constant in the swallowing problems model. For this reason
the actual selection accuracy due to uncertainty in NTCP
models might be somewhat lower for this model.
The guidelines of the Dutch Society of Radiation Oncology
allow the addition of DNTCPs from different models before
making the selection. It would be interesting to investigate if
certain combinations would lead to improved selection
accuracy.
We showed that the accuracy of model-based patient
selection for proton therapy is highly affected by uncertain-
ties in NTCP models and uncertainties resulting from differen-
ces between planned and delivered dose variables. Since
accurate patient selection for IMPT is of utmost importance,
we recommend that the uncertainty in NTCP models is
reduced by analyzing sufficiently large patient cohorts and
by external validation of the models. Furthermore, since the
reduction of selection accuracy appeared to be most severe
in the region of the currently proposed DNTCP thresholds,
the difference between planned and delivered doses should
be kept as low as possible.
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